Dylan J. Kahl, Ph.D.

Dylan manages patent portfolios for companies developing cutting-edge therapeutics and life science technologies, helping companies develop patent assets during early-stage discovery, clinical trials and beyond. His work supports clients in securing the intellectual property protection needed to advance research, attract investment and successfully commercialize their innovations. Over the course of his career, Dylan has helped companies obtain critical funding by aligning patent procurement with business objectives, enabling patent portfolios that both protect scientific advances and strengthen competitive position. He brings extensive experience in drafting and prosecuting patent applications, responding to domestic and international office actions, and advising companies in fields ranging from pharmaceuticals and biopharmaceuticals to emerging clean technologies.

Representative Experience

As a skilled patent agent, Dylan provides patent support to companies and investment firms involved in small-molecule therapeutics, peptide therapeutics, antibody drug conjugates (ADCs), molecular glues, PROTACs, chemical processes, clean technologies and other technologies in the chemistry space. Dylan has supported IP diligence for venture financings, public offerings and strategic transactions. He supports processes that enable companies and investors alike to understand the strength, scope and value of patent assets, positioning them for long-term growth and competitive advantage. Whether helping a start-up file its first patent application or supporting patent due diligence for a multimillion-dollar investment or public offering, Dylan provides skills and capabilities that are both scientifically rigorous and commercially informed.

Technical Experience

With a Ph.D. in medicinal chemistry, Dylan brings a deep scientific foundation to his patent practice. His technical experience informs his practice in a wide range of fields critical to modern innovation, including small-molecule therapeutics, mRNA and gene therapies, protein and cell therapies, pharmaceutical formulations, nucleic acid and protein sequencing, and synthetic biology. Beyond life sciences, he also works with technologies in food science, chemical separation processes, energy production and storage materials, biomaterials, and metals. This breadth of knowledge allows him to engage meaningfully with inventors, research teams and executives, translating complex discoveries into clear, enforceable intellectual property rights. By bridging the gap between advanced science and strategic business objectives, Dylan enables companies to protect innovations in competitive and rapidly evolving industries.